EFFECTS OF REBOXETINE & NEFAZODONE ON PHARMACOKINETICS OF ALPRAZOLAM

瑞博西汀的作用

• 批准号: 6450072
• 负责人: LARRY ERESHEFSKY
• 金额: $ 23.48万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6450072
• 关键词: alprazolam; antidepressants; clinical research; drug interactions; human subject; human therapy evaluation; pharmacokinetics; serotonin inhibitor

Reboxetine, a selective norepinepherine reuptake inhibitor, is an investigational antidepressant which is approved for use in several European countries and for which an NDA will be submitted to the FDA for approval. Once approved, it will join an array of antidepressants which have largely replaced the tricyclic antidepressants. The purpose of this study is to determine whether the pharmacokinetics and pharmacodynamics of alprazolam, a drug whose metabolism is mandated in part by the CYP3A4 isoenzyme, is altered by the administration of reboxetine which is thought to inhibit CYP3A4. The effect of reboxetine on alprazolam will also be compared to that of nefazodone, a seratonin-uptake inhibitor.

瑞波西汀是一种选择性去甲肾上腺素再摄取抑制剂，是一种在研抗抑郁药，已获准在多个欧洲国家使用，并将向 FDA 提交 NDA 审批。 一旦获得批准，它将加入一系列抗抑郁药的行列，在很大程度上取代了三环类抗抑郁药。 本研究的目的是确定阿普唑仑（一种其代谢部分由 CYP3A4 同工酶控制的药物）的药代动力学和药效学是否因服用瑞波西汀而改变，瑞波西汀被认为可以抑制 CYP3A4。 瑞波西汀对阿普唑仑的作用也将与奈法唑酮（一种血清素摄取抑制剂）的作用进行比较。